Association Between Clinical Measures and Florbetapir F18 PET Neuroimaging in Mild or Moderate Alzheimer’s Disease Dementia
Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
Abstract
Clinical diagnosis of Alzheimer’s disease (AD) is challenging, with 20% or more of patients misdiagnosed, even by expert clinicians. The authors conducted a retrospective, cross-sectional analysis comparing baseline neuropsychiatric and other clinical characteristics in 199 expert-diagnosed mild and moderate AD dementia patients participating in industry-sponsored clinical trials of an investigational therapy, where 18% lacked florbetapir positron emission tomography (PET) evidence of AD neuropathology. Significant differences were found only for cognition and ApoE ε4 status, but the large degree of score overlap would preclude using these measures to predict AD misdiagnosis. This study highlights the value of amyloid PET when evaluating patients with seemingly typical AD.
Research using biological evidence of underlying Alzheimer’s disease (AD) neuropathology reports both over- and under-diagnosis of possible or probable AD dementia, even when expert clinicians use specific diagnostic criteria. Autopsy reports have shown that a significant number of patients diagnosed clinically by dementia specialists as having probable AD in fact lack AD pathology.1,2 For example, a recent study comparing expert clinical diagnoses for possible or probable AD and neuropathology at autopsy using the National Alzheimer’s Coordinating Center database found positive predictive values from 57.6% to 83.3%, with sensitivities from 70.9% to 87.3%, and specificities from 44.3% to 70.8% depending upon the stringency of neuropathological criteria used.2
To improve diagnostic accuracy, the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria3 were revised in 2011 by the National Institute of Aging and the Alzheimer’s Association (NIA/AA), where clinical diagnoses can be made with or without supporting biomarker evidence for AD.4,5 These biomarkers, as stated in the criteria, are meant primarily for research purposes and include those that assess beta-amyloid (Aβ) pathology (measuring cerebrospinal fluid [CSF], Aβ42, or amyloid plaque on positron emission tomography [PET] neuroimaging), or those reflecting the effects of neurodegeneration (measuring CSF-tau, atrophy on magnetic resonance imaging [MRI], or metabolism using 18F-fluorodeoxyglucose PET).
Florbetapir (18F-AV−45, FBP) is a PET ligand for the estimation of Aβ neuritic plaque density, and has been commercially available in the United States since 2012. The in vivo detection of Aβ neuritic plaque density in cortical gray matter with FBP-PET has been shown to correlate with the presence and density of Aβ plaques detected pathologically postmortem using Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) criteria where zero to sparse plaques are inconsistent with AD, and moderate to frequent plaques are consistent with AD.6,7 A standardized uptake value ratio (SUVR) cut-off of 1.1 has been proposed for quantitative determination of positive or negative scans.6,7 FBP-PET has been validated both by autopsy pathology in end-of-life patients6,7 and also in earlier stage patients as compared with results from the 11C-labeled amyloid-PET ligand, Pittsburgh compound B (PiB).8 When compared with postmortem histological diagnosis, FBP-PET showed 3% false-negative and 0% false-positive rates.7
In this study of a subgroup of patients with a clinical diagnosis (using NINCDS-ADRDA criteria) of mild or moderate probable AD dementia who were participating in a treatment trial, we investigated whether baseline characteristics differed between subjects who had a positive or a negative FBP-PET scan per quantitative cut-off method. The purpose was to identify clinical characteristics associated with either a positive or a negative FBP-PET scan, which could be used by clinicians to identify patients at greater risk for being clinically misdiagnosed as AD.
Methods
Subjects and Design
Baseline (pre-study drug administration) demographic, cognitive, neuropsychiatric, and FBP-PET data were obtained from a pooled subset of 199 patients (out of a total pooled population of 2,648) who enrolled in an optional imaging addendum to two multisite randomized registration trials of an investigational anti-Aβ therapy, semagacestat. The imaging addendum was available for any investigator and patient who wanted to participate if they were in an investigative site with access to FBP-PET. Both trials, IDENTITY (H6L-MC-LFAN; NCT00594568) and IDENTITY−2 (H6L-MC-LFBC; NCT00762411), had identical entry criteria and enrolled male and female patients ≥55 years old with a NINCDS-ADRDA criteria diagnosis of probable AD. Inclusion was a Mini Mental State Exam (MMSE) score between 20 and 26 (inclusive) for mild stage dementia or between 16 and 19 (inclusive) for moderate stage. Females could no longer be of child-bearing potential. Patients were excluded from the trials for stroke, unstable medical illness, substance abuse/dependence, major depression, or vascular dementia. A MRI or computerized tomography (CT) scan had to have been performed within the preceding 2 years to confirm no findings were inconsistent with a diagnosis of AD.
Protocols were reviewed and approved by institutional review boards, and all patients and caregivers provided written informed consent according to the Declaration of Helsinki. A further description of the studies can be found in the report of Carlson et al.9
Rating Scales
The following rating scales were administered to patients at baseline; that is, at the time of randomization: The Alzheimer’s Disease Assessment Scale: a cognitive subscale 14-item version (ADAS-Cog14),10,11 which has a score range of 0–90, where higher scores indicate greater impairment; the Alzheimer’s Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL),12,13 which has a score range of 0–78, where higher scores indicate greater independence in the performance of ADLs; the Clinical Dementia Rating–Sum of Boxes (CDR-SB),14 which has a score range on a scale of 0–18,15 where higher scores indicate more severe impairment; the MMSE,16 which has a score range of 0 (very impaired)–30 (normal); and the Neuropsychiatric Inventory (NPI),17 a 12-item assessment of psychopathology in neurologically impaired patients, where scores range from 0–144. Also included were the mood, frontal, and agitation subscales in addition to a two-item psychosis measure18–21 and the Geriatric Depression Scale (GDS).22 The GDS has a score range from 0–15, where higher scores indicate more symptoms and a cut-off of 7 points is consistent with syndromal depression.22 Patients had to score ≤6 to be eligible for the IDENTITY studies.
Neuroimaging
FBP-PET neuroimaging was performed on a subset of trial participants who agreed to participate in the optional addendum to these trials. Florbetapir F18 [(E)−4-(2-(6-(2-(2-(2–18F-fluoroethoxy)ethoxy)ethoxy)pyridin−3-yl)vinyl)-N-methyl benzenamine] was prepared by the method of Choi et al.23 PET imaging was performed 50 minutes (±5 mins) after intravenous administration of 370 MBq of FBP. Images were obtained over 30 mins (6×5-mins 3D emission scans). Data for attenuation correction were collected via a transmission scan and obtained either before or after the emission scan. Following acquisition, the images were reconstructed via iterative algorithms. Quantitative analyses were performed by normalizing the summed PET frames to a standard template in Talairach space and obtaining a SUVR for a composite of cortical regions of interest (ROI) (frontal, temporal, parietal, precuneus, anterior cingulate, and posterior cingulate). The entire cerebellum was used as the reference region. Patients with a composite cortical SUVR ≥1.1 were considered to have a positive scan.6,7
Statistical Analyses
Baseline data from the subsets of patients from the IDENTITY and IDENTITY−2 trials who received FBP-PET neuroimaging were pooled for these retrospective, cross-sectional analyses. The demographic, rating scale, and cognitive data were compared by either a two-tailed Fisher’s exact test (for categorical variables) or analysis of variance (ANOVA, for continuous variables) between groups of patients categorized as positive or negative for Aβ on FBP-PET. Correlations between the composite SUVR and age or years of education were assessed using the Pearson product-moment correlation test.
Results
As summarized in Table 1, of the 199 patients across the two trials who underwent FBP-PET imaging at baseline, 164 (82%) were categorized as positive (SUVR ≥1.1) and 35 (18%) as negative for amyloid plaque (see Figure 1 for examples of a negative and positive scan). Negative and positive groups had a similar mean age (74.3 versus 75.5 years; p=0.449) and years of education (14.8 versus 14.9 years; p=0.809), and neither age (r=−0.002; p=0.980) nor years of education (r=−0.008; p=0.915) were found to correlate with the FBP-PET composite SUVR (data not shown). The FBP-PET negative scan group had a significantly lower proportion of females (37% versus 58%; p=0.039), were significantly more likely to have a clinical diagnosis of mild stage (MMSE 20–26) AD dementia (86% versus 59% in the negative scan and positive scan groups, respectively; p=0.003), and were significantly more likely to be noncarriers of the ApoE ε4 allele (82% versus 33% in the negative scan and positive scan groups, respectively; p<0.001). There was no significant effect of race observed (data not shown).
| Variable | Positive FBP-PET (N=164) | Negative FBP-PET (N=35) | p-valueb |
|---|---|---|---|
| Demographic and dementia staging | |||
| Age (years) | 75.5±8.04 (56–90) | 74.3±8.52 (56–91) | 0.449 |
| Education (years) | 14.9±3.15 (6–27) | 14.8±3.53 (7–22) | 0.809 |
| Sex, female, n (%) | 95 (57.9) | 13 (37.1) | 0.039 |
| AD dementia stage, n (%) | 0.003 | ||
| Mild (MMSE 20–26) | 94 (59.1) | 30 (85.7) | |
| Moderate (MMSE 16–19) | 65 (40.9) | 5 (14.3) | |
| MMSE Total Score | 20.5±3.98 (13–30) | 23.5±3.21 (15–30) | <0.001 |
| FBP-PET | |||
| Composite SUVR | 1.49±0.21 (1.12–2.15) | 0.95±0.09 (0.77–1.09) | <0.001 |
| Genomic blood tests | |||
| ApoE ε4 alleles, n (%) | <0.001 | ||
| 0 | 46 (32.6) | 27 (81.8) | |
| 1 | 66 (46.8) | 5 (15.2) | |
| 2 | 29 (20.6) | 1 (3.0) | |
| Cognitive measures | |||
| ADAS-Cog14 | 34.1±10.7 (11–63) | 26.8±12.4 (8–63) | <0.001 |
| CDR-SB | 5.19±2.80 (0.50–13.0) | 4.44±2.86 (0.50–11.0) | 0.158 |
| MMSE, (maximum possible score) | |||
| Attention and calculation (5) | 2.54±1.77 (0–5) | 3.17±1.64 (0–5) | 0.055 |
| Language (9) | 7.90±1.20 (3–9) | 8.40±0.55 (7–9) | 0.018 |
| Orientation (10) | 6.36±2.29 (1–10) | 7.66±2.13 (2–10) | 0.002 |
| Registration (3) | 2.95±0.28 (1–3) | 2.94±0.24 (2–3) | 0.929 |
| Recall (3) | 0.81±1.02 (0–3) | 1.31±1.11 (0–3) | 0.010 |
| Rating scales | |||
| ADCS-ADL | 62.4±11.6 (29–78) | 63.8±11.6 (32–78) | 0.527 |
| NPI | |||
| Mood subscale | 3.36±4.52 (0–22) | 2.69±4.98 (0–27) | 0.434 |
| Agitation/aggression subscale | 3.13±4.85 (0–29) | 4.83±8.88 (0–27) | 0.121 |
| Frontal subscale | 4.01±5.35 (0–29) | 4.40±6.43 (0–33) | 0.712 |
| Total score | 10.9±12.1 (0–58) | 12.1±16.9 (0–88) | 0.643 |
| GDS | 1.51±1.42 (0–7) | 2.23±1.70 (0–6) | 0.010 |
Data are expressed as means±SD (range) or within group n (%) as appropriate and p values are between positive and negative scan groups. AD: Alzheimer’s disease; ADAS-Cog14: Alzheimer’s disease assessment scale – cognitive subscale 14-item version; ADCS-ADL: Alzheimer’s disease cooperative study activities of daily living inventory; CDR-SB: clinical dementia rating – sum of boxes; FBP: 18fluorine-labelled florbetapir; GDS: geriatric depression scale; MMSE: mini mental-state exam; NPI: neuropsychiatric inventory; PET: positron emission tomography; SD: standard deviation; SUVR: standardized uptake value ratio.
a
FBP-PET scans were categorized as either positive or negative for the presence of abnormal levels of Aβ plaque using a cutoff value of ≥1.1.
b Frequencies are analyzed using Fisher’s exact test, means by analysis-of-variance.
FIGURE 1. Representative FBP-PET Images for Two Subjects
FBP-PET positive scan (top row, SUVR=2.13) and FBP-PET negative scan (bottom row, SUVR=1.01), show a difference of florbetapir uptake between the subjects in lateral temporal, precuneus, lateral frontal, and posterior cingulate cortical regions. Prespecified SUVR threshold of 1.10 (with respect to cerebellum as a reference region) was used to define florbetapir positivity. Transverse (left) and sagittal images (right) are shown at the same level in both subjects.
The FBP-PET negative scan group performed significantly better on the baseline ADAS-Cog14 and MMSE than the positive group; however, both groups scored in the abnormal range. There was no distinguishing pattern of abnormalities in the items of the MMSE. In contrast, patients in the FBP-PET negative scan group had a worse performance on the GDS than those in the positive scan group [mean (standard deviation, SD): 2.23 (1.70) versus 1.51 (1.42); p=0.010]. No difference between the FBP-PET negative and positive scan groups were found on the ADCS-ADL [mean (SD): 63.8 (11.6) versus 62.4 (11.6); p=0.527], CDR-SB [mean (SD): 4.44 (2.86) versus 5.19 (2.80) ; p=0.158], the NPI total score [mean (SD): 12.1 (16.9) versus 10.9 (12.1) ; p=0.643], or any of the three NPI subscales.
In contrast to the results of patients with a clinical diagnosis of mild AD, of whom 24% had negative FBP-PET scans, among all patients with a clinical diagnosis of moderate stage AD dementia only 7% were in the FBP-PET negative group and 93% had positive FBP-PET scans. Among all ApoE ε4 carriers, only 6% were in the FBP-PET negative group whereas 94% were in the FBP-PET positive group. Among ApoE ε4 noncarriers, 37% had negative FBP-PET scans.
Discussion
We retrospectively analyzed pooled clinical and FBP-PET scan data from the pretreatment baseline visits from two industry-sponsored clinical trials with identical entry criteria for 199 patients who had been clinically diagnosed by dementia experts using NINCDS-ADRDA criteria as having mild or moderate probable AD dementia. Overall, we found that 35 patients (18%) had a negative FBP-PET scan; that is, they lacked evidence of amyloid pathology despite having received a clinical diagnosis of AD. Negative FBP-PET scans were more common in ApoE ε4 noncarriers and patients with mild AD dementia.
Sperling and colleagues26 reported at the 2012 Clinical Trials in Alzheimer’s Disease conference that 16% of patients enrolled in two trials of an investigational antiamyloid treatment (bapineuzumab) had negative amyloid-PET results (using 11C-PiB). In that same report, and similar to our findings, 36% of ApoE ε4 noncarriers were PiB-PET negative compared with only 7% of ApoE ε4 carriers. Similarly, Johnson et al.27 recently reported that 16% of patients in another study who had been clinically diagnosed (NINCDS-ADRDA) with AD dementia (MMSE ≤24) were FBP-PET negative, all of whom were ApoE ε4 noncarriers. Landau et al.25 analyzed data from the Alzheimer’s Disease Neuroimaging Initiative and reported 23% of all clinically diagnosed AD dementia patients in their study were FBP-PET negative. Additionally, Fleischer et al.28 reported that 15% of clinically diagnosed AD dementia patients in their cohort were found to be FBP-PET negative.
The FBP-PET negative scan group showed significantly less impairment on the ADAS-Cog14 and MMSE (both p<0.001), and fewer of these patients were in the moderate AD severity group compared with those with FBP-PET positive amyloid scans. The finding of a relationship between more cognitive impairment and FBP-PET scanning is consistent with recent research showing a significant positive correlation between cognitive impairment and FBP-PET SUVR values.24 Landau et al.25 also reported a significant positive correlation between amyloid load using FBP-PET and cognitive impairment using the ADAS-Cog in early mild cognitive impairment (MCI) (r=0.24; p=0.002) and late MCI patients (r=0.29; p=0.007).
As would be expected, patients in our FBP-PET negative scan group were also less likely to be ApoE ε4 allele carriers, where ApoE ε4 is a well-known risk factor for amyloid and AD. Additionally, although patients with syndromal major depression at baseline were excluded from our studies, patients in the negative scan group exhibited significantly higher levels of depression symptoms than the positive scan group. However, the clinical significance of this finding is unclear because the mean baseline GDS scores for both groups were well below the cut-off for syndromal depression.
We focused on the baseline data acquired at the trials’ pretreatment visit in order to better simulate and inform clinical practice. We sought to identify variables that could be used by clinicians at this stage to identify patients at greater risk for being clinically misdiagnosed as AD. Although we detected some differences between scan positive and scan negative groups, the most striking finding was that few clinical descriptors distinguished these groups. While negative FBP-PET scans were more common in ApoE ε4 noncarriers and patients with mild AD dementia, suggesting diagnosis may be more difficult in these patients, there was a large degree of overlap in the ranges of cognitive scores and demographic characteristics between the groups (Table 1), and none of those factors are sufficient for an accurate prediction of which demented patients diagnosed with probable AD per clinical criteria lacked Aβ neuropathology.
In addition to clinical practice, these data also support the idea that the use of biomarkers in the patient selection process can add value to AD clinical trials where investigational treatments are being studied in both dementia and MCI populations. This would enhance the detection of an efficacy signal in the trial and decrease exposure of patients who do not have AD to risks associated with investigational medicines. Further research is needed across all phases of AD to understand the relationship among various biomarkers and their place in the clinic.
A limitation of our report is that only the subset of 199 patients underwent FBP-PET neuroimaging and they may not be representative of the larger study sample; nonetheless, the proportion (18%) who were diagnosed as having AD by dementia specialists but had no amyloid biomarker evidence for AD mirrored that reported in the literature.1,2,25,27,28 We cannot speculate as to the negative-scan patients’ true causes of dementia. However, in a different type of patient cohort, Beach et al.2 reported a wide variety of pathological findings on autopsy for those who were misdiagnosed antemortem without the benefit of amyloid imaging, including tau-only dementia, frontotemporal lobar dementia, and cerebrovascular disease. Finally, we used a quantitative method to determine dichotomous scan status (positive or negative for amyloid). Using a qualitative read may have resulted in different findings, although there is high comparability between these methods.6,7
The value of a FBP-PET scan for a more accurate AD diagnosis is highlighted by our findings in demented patients. Our findings add to a growing literature about the challenges of making an accurate diagnosis solely on clinical phenotype even where structural neuroimaging has excluded other etiologies.
Conclusions
A certain diagnosis of AD remains challenging to the clinician and researcher without antemortem confirmation of Alzheimer’s pathology. Although diagnosed by expert clinicians, 18% of patients with probable AD dementia in this study had FBP-PET results inconsistent with a diagnosis of AD. The Aβ-positive FBP-PET scan group demonstrated significant deficits on several cognitive tests compared with patients with negative scans at baseline; however, there was a large degree of overlap between the groups and no single factor can be said to predict a negative scan. This study highlights the importance of amyloid neuroimaging in the AD diagnostic matrix. The use of FBP-PET could provide valuable assistance to clinicians in their assessment of patients presenting with cognitive deficits.
Acknowledgments
The authors report that they are employees of Eli Lilly. All authors except Dr. Quinlivan are minor shareholders with Eli Lilly.
This study was supported by Eli Lilly.
The authors thank all the patients who participated in this study and the optional imaging addendum.
References
1.
Mayeux R, Saunders AM, Shea S, et al.; Alzheimer’s Disease Centers Consortium on Apolipoprotein E and Alzheimer’s Disease: Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. N Engl J Med 1998; 338:506–511
2.
Beach TG, Monsell SE, Phillips LE, et al.: Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J Neuropathol Exp Neurol 2012; 71:266–273
3.
McKhann G, Drachman D, Folstein M, et al.: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34:939–944
4.
McKhann GM, Knopman DS, Chertkow H, et al.: The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7:263–269
5.
Jack CR, Albert MS, Knopman DS, et al.: Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7:257–262
6.
Clark CM, Schneider JA, Bedell BJ, et al.; AV45-A07 Study Group: Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305:275–283
7.
Clark CM, Pontecorvo MJ, Beach TG, et al.; AV-45-A16 Study Group: Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 2012; 11:669–678
8.
Landau SM, Breault C, Joshi AD, et al.; Alzheimer’s Disease Neuroimaging Initiative: Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 2013; 54:70–77
9.
Carlson C, Estergard W, Oh J, et al.: Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer’s disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement 2011; 7:396–401
10.
Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141:1356–1364
11.
Mohs RC, Knopman D, Petersen RC, et al.: Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(Suppl 2):S13–S21
12.
Galasko D, Bennett D, Sano M, et al.: An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(Suppl 2):S33–S39
13.
Galasko D, Kershaw PR, Schneider L, et al.: Galantamine maintains ability to perform activities of daily living in patients with Alzheimer’s disease. J Am Geriatr Soc 2004; 52:1070–1076
14.
Berg L, Miller JP, Baty J, et al.: Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Neurol 1992; 31:242–249
15.
Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43:2412–2414
16.
Folstein MF, Folstein SE, McHugh PR: “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189–198
17.
Cummings JL, Mega M, Gray K, et al.: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308–2314
18.
Aalten P, Verhey FR, Boziki M, et al.: Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord 2007; 24:457–463
19.
Aalten P, Verhey FR, Boziki M, et al.: Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II. Dement Geriatr Cogn Disord 2008; 25:1–8
20.
Dennehy EB, Kahle-Wrobleski K, Sarsour K, et al.: Derivation of a brief measure of agitation and aggression in Alzheimer’s disease. Int J Geriatr Psychiatry 2013; 28:182–189
21.
Trzepacz PT, Saykin A, Bhamditipati P, et al.: Subscale validation of the neuropsychiatric inventory questionnaire: Comparison of Alzheimer’s disease neuroimaging initiative and national Alzheimer’s coordinating center cohorts. Am J Geriatr Psychiatry 2013; 21:607–622
22.
Sheikh J, Yesavage J: Geriatric Depression Scale (GDS): recent evidence and development of the shorter version. Clin Gerontol 1986; 5:165–173
23.
Choi SR, Golding G, Zhuang Z, et al.: Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 2009; 50:1887–1894
24.
Rosenberg PB, Wong DF, Edell SL, et al.: Cognition and amyloid load in alzheimer disease imaged with florbetapir F 18 (AV-45) positron emission tomography. Am J Geriatr Psychiatry 2013; 2:272–278
25.
Landau SM, Mintun MA, Joshi AD, et al.; Alzheimer’s Disease Neuroimaging Initiative: Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012; 72:578–586
26.
Sperling R, Salloway S, Raskind M, et al: Bapineuzumab phase 3 trials in mild to moderate Alzheimer’s disease dementia in apolipoprotein E e4 carriers (study 302) and non-carriers (study 301) 2012; http://www.ctad.fr/07-download/Congres2012/PressRelease/Final-Sperling-CTAD-Presentation-10-29-12.pdf; accessed Feb 11, 2013
27.
Johnson KA, Sperling RA, Gidicsin CM, et al.: Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 2013; 9(Suppl 5):S72–S83
28.
Fleisher AS, Chen K, Liu X, et al.: Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011; 68:1404–1411
Information & Authors
Information
Published In
History
Received: 18 December 2012
Revision received: 21 March 2013
Accepted: 22 April 2013
Published online: 1 July 2014
Published in print: Summer 2014
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).